ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
7 announcements
Sudarshan Pharma Industries Ltd held its 18th Annual General Meeting on September 22, 2026. The meeting covered the adoption of financial statements and director re-appointment.
Sudarshan Pharma stated its proposed 9.50% stake acquisition of Med Therapy Biotechnology Inc. remains under due diligence. Promoter acquisitions of 1.50% each are also pending.
Sudarshan Pharma Industries Ltd announced the release of a pledge of 20,00,000 equity shares held by its promoter, Mr. Hemal Mehta. This disclosure complies with SEBI regulations.
Sudarshan Pharma Industries will acquire a 9.50% stake in MedTherapy Biotechnology Inc. for cash. Its promoters will separately acquire an additional 3% combined stake.
Sudarshan Pharma Industries reports on its specialty chemicals and pharmaceutical business, highlighting the turnaround of Ratna Lifescience and strategic vertical integration into API manufacturing and branded generics.
Sudarshan Pharma Industries Ltd reported revenue from operations of ₹174.4 Cr (+20.0% YoY) and net profit of ₹5.6 Cr (+40.0% YoY) for Q1 FY27.
Sudarshan Pharma Industries Ltd reported revenue from operations of ₹220.9 Cr (+36.7% YoY) and net profit of ₹11.4 Cr (+54.1% YoY) for Q4 FY26.